广济药业:2024年报净利润-2.95亿 同比下降110.71%

Financial Performance - The company reported a basic earnings per share of -0.8392 yuan for 2024, a decrease of 111.81% compared to -0.3962 yuan in 2023 [1] - The net profit for 2024 was -2.95 billion yuan, reflecting a decline of 110.71% from -1.4 billion yuan in 2023 [1] - The return on equity (ROE) was -24.43% in 2024, a significant drop from -9.79% in 2023 [1] - Total revenue decreased to 6.39 billion yuan in 2024, down 13.41% from 7.38 billion yuan in 2023 [1] - The net asset per share fell to 3.04 yuan, a decrease of 21.04% from 3.85 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 13,395.37 million shares, accounting for 38.93% of the circulating shares, with a decrease of 319,300 shares compared to the previous period [2] - Changjiang Industrial Investment Group Co., Ltd. remains the largest shareholder with 8,759.21 million shares, representing 25.46% of the total share capital [3] - New entrants among the top shareholders include Hu Zuping and Jin Qingyu, while Wang Chenghua and Li Weihua have exited the top ten list [3] Dividend Policy - The company has announced no distribution or capital increase for the current period [4]